The Gene Therapy Resource Program: A Decade of Dedication to Translational Research by the National Heart, Lung, and Blood Institute

Terence R. Flotte, Eric Daniels, Janet Benson, Jeneé M. Bevett-Rose, Kenneth Cornetta, Margaret Diggins, Julie Johnston, Susan Sepelak, Johannes C.M. Van Der Loo, James M. Wilson, Cheryl L. McDonald

Research output: Contribution to journalReview article

Abstract

Over a 10-year period, the Gene Therapy Resource Program (GTRP) of the National Heart Lung and Blood Institute has provided a set of core services to investigators to facilitate the clinical translation of gene therapy. These services have included a preclinical (research-grade) vector production core; current Good Manufacturing Practice clinical-grade vector cores for recombinant adeno-associated virus and lentivirus vectors; a pharmacology and toxicology core; and a coordinating center to manage program logistics and to provide regulatory and financial support to early-phase clinical trials. In addition, the GTRP has utilized a Steering Committee and a Scientific Review Board to guide overall progress and effectiveness and to evaluate individual proposals. These resources have been deployed to assist 82 investigators with 172 approved service proposals. These efforts have assisted in clinical trial implementation across a wide range of genetic, cardiac, pulmonary, and blood diseases. Program outcomes and potential future directions of the program are discussed.

Original languageEnglish (US)
Pages (from-to)178-186
Number of pages9
JournalHuman Gene Therapy Clinical Development
Volume28
Issue number4
DOIs
StatePublished - Dec 1 2017

Fingerprint

National Heart, Lung, and Blood Institute (U.S.)
Translational Medical Research
Anniversaries and Special Events
Genetic Therapy
Research Personnel
Clinical Trials
Financial Support
Dependovirus
Lentivirus
Inborn Genetic Diseases
Hematologic Diseases
Toxicology
Lung Diseases
Heart Diseases
Pharmacology
Research

Keywords

  • adeno-associated virus
  • clinical trial
  • Gene therapy
  • lentivirus
  • preclinical
  • vector

ASJC Scopus subject areas

  • Genetics(clinical)

Cite this

The Gene Therapy Resource Program : A Decade of Dedication to Translational Research by the National Heart, Lung, and Blood Institute. / Flotte, Terence R.; Daniels, Eric; Benson, Janet; Bevett-Rose, Jeneé M.; Cornetta, Kenneth; Diggins, Margaret; Johnston, Julie; Sepelak, Susan; Van Der Loo, Johannes C.M.; Wilson, James M.; McDonald, Cheryl L.

In: Human Gene Therapy Clinical Development, Vol. 28, No. 4, 01.12.2017, p. 178-186.

Research output: Contribution to journalReview article

Flotte, TR, Daniels, E, Benson, J, Bevett-Rose, JM, Cornetta, K, Diggins, M, Johnston, J, Sepelak, S, Van Der Loo, JCM, Wilson, JM & McDonald, CL 2017, 'The Gene Therapy Resource Program: A Decade of Dedication to Translational Research by the National Heart, Lung, and Blood Institute', Human Gene Therapy Clinical Development, vol. 28, no. 4, pp. 178-186. https://doi.org/10.1089/humc.2017.170
Flotte, Terence R. ; Daniels, Eric ; Benson, Janet ; Bevett-Rose, Jeneé M. ; Cornetta, Kenneth ; Diggins, Margaret ; Johnston, Julie ; Sepelak, Susan ; Van Der Loo, Johannes C.M. ; Wilson, James M. ; McDonald, Cheryl L. / The Gene Therapy Resource Program : A Decade of Dedication to Translational Research by the National Heart, Lung, and Blood Institute. In: Human Gene Therapy Clinical Development. 2017 ; Vol. 28, No. 4. pp. 178-186.
@article{ec44f116cb914663bcd2d362a7dc842c,
title = "The Gene Therapy Resource Program: A Decade of Dedication to Translational Research by the National Heart, Lung, and Blood Institute",
abstract = "Over a 10-year period, the Gene Therapy Resource Program (GTRP) of the National Heart Lung and Blood Institute has provided a set of core services to investigators to facilitate the clinical translation of gene therapy. These services have included a preclinical (research-grade) vector production core; current Good Manufacturing Practice clinical-grade vector cores for recombinant adeno-associated virus and lentivirus vectors; a pharmacology and toxicology core; and a coordinating center to manage program logistics and to provide regulatory and financial support to early-phase clinical trials. In addition, the GTRP has utilized a Steering Committee and a Scientific Review Board to guide overall progress and effectiveness and to evaluate individual proposals. These resources have been deployed to assist 82 investigators with 172 approved service proposals. These efforts have assisted in clinical trial implementation across a wide range of genetic, cardiac, pulmonary, and blood diseases. Program outcomes and potential future directions of the program are discussed.",
keywords = "adeno-associated virus, clinical trial, Gene therapy, lentivirus, preclinical, vector",
author = "Flotte, {Terence R.} and Eric Daniels and Janet Benson and Bevett-Rose, {Jene{\'e} M.} and Kenneth Cornetta and Margaret Diggins and Julie Johnston and Susan Sepelak and {Van Der Loo}, {Johannes C.M.} and Wilson, {James M.} and McDonald, {Cheryl L.}",
year = "2017",
month = "12",
day = "1",
doi = "10.1089/humc.2017.170",
language = "English (US)",
volume = "28",
pages = "178--186",
journal = "Human gene therapy. Clinical development",
issn = "2324-8637",
publisher = "Mary Ann Liebert Inc.",
number = "4",

}

TY - JOUR

T1 - The Gene Therapy Resource Program

T2 - A Decade of Dedication to Translational Research by the National Heart, Lung, and Blood Institute

AU - Flotte, Terence R.

AU - Daniels, Eric

AU - Benson, Janet

AU - Bevett-Rose, Jeneé M.

AU - Cornetta, Kenneth

AU - Diggins, Margaret

AU - Johnston, Julie

AU - Sepelak, Susan

AU - Van Der Loo, Johannes C.M.

AU - Wilson, James M.

AU - McDonald, Cheryl L.

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Over a 10-year period, the Gene Therapy Resource Program (GTRP) of the National Heart Lung and Blood Institute has provided a set of core services to investigators to facilitate the clinical translation of gene therapy. These services have included a preclinical (research-grade) vector production core; current Good Manufacturing Practice clinical-grade vector cores for recombinant adeno-associated virus and lentivirus vectors; a pharmacology and toxicology core; and a coordinating center to manage program logistics and to provide regulatory and financial support to early-phase clinical trials. In addition, the GTRP has utilized a Steering Committee and a Scientific Review Board to guide overall progress and effectiveness and to evaluate individual proposals. These resources have been deployed to assist 82 investigators with 172 approved service proposals. These efforts have assisted in clinical trial implementation across a wide range of genetic, cardiac, pulmonary, and blood diseases. Program outcomes and potential future directions of the program are discussed.

AB - Over a 10-year period, the Gene Therapy Resource Program (GTRP) of the National Heart Lung and Blood Institute has provided a set of core services to investigators to facilitate the clinical translation of gene therapy. These services have included a preclinical (research-grade) vector production core; current Good Manufacturing Practice clinical-grade vector cores for recombinant adeno-associated virus and lentivirus vectors; a pharmacology and toxicology core; and a coordinating center to manage program logistics and to provide regulatory and financial support to early-phase clinical trials. In addition, the GTRP has utilized a Steering Committee and a Scientific Review Board to guide overall progress and effectiveness and to evaluate individual proposals. These resources have been deployed to assist 82 investigators with 172 approved service proposals. These efforts have assisted in clinical trial implementation across a wide range of genetic, cardiac, pulmonary, and blood diseases. Program outcomes and potential future directions of the program are discussed.

KW - adeno-associated virus

KW - clinical trial

KW - Gene therapy

KW - lentivirus

KW - preclinical

KW - vector

UR - http://www.scopus.com/inward/record.url?scp=85038617105&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85038617105&partnerID=8YFLogxK

U2 - 10.1089/humc.2017.170

DO - 10.1089/humc.2017.170

M3 - Review article

C2 - 29130351

AN - SCOPUS:85038617105

VL - 28

SP - 178

EP - 186

JO - Human gene therapy. Clinical development

JF - Human gene therapy. Clinical development

SN - 2324-8637

IS - 4

ER -